{"transactions":[{"id":2529255,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":134013,"kind":"person","name":"Daigneault Alessandra","position":1,"cik":"0001864648","reported_name":"Daigneault Alessandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Restricted Stock Units","published_at":"2021-11-02T16:05:45.000Z","date":"2021-09-02","kind":"grant","acquired":true,"shares":7502,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Shares and restricted stock units acquired pursuant to the exercise of 20,666 vested stock options under the Plan. The Reporting person received 13,164 freely tradable shares of Common Stock and 7,502 restricted stock units under the Plan, each restricted stock unit representing a right to receive one share of Common Stock. These restricted stock units remain in the Plan and are subject to forfeiture if the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) do not occur on or prior to December 31, 2022."},{"field":"shares","element":"transactionShares","label":"F3","text":"Shares and restricted stock units acquired pursuant to the exercise of 20,666 vested stock options under the Plan. The Reporting person received 13,164 freely tradable shares of Common Stock and 7,502 restricted stock units under the Plan, each restricted stock unit representing a right to receive one share of Common Stock. These restricted stock units remain in the Plan and are subject to forfeiture if the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) do not occur on or prior to December 31, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Shares and restricted stock units acquired pursuant to the exercise of 20,666 vested stock options under the Plan. The Reporting person received 13,164 freely tradable shares of Common Stock and 7,502 restricted stock units under the Plan, each restricted stock unit representing a right to receive one share of Common Stock. These restricted stock units remain in the Plan and are subject to forfeiture if the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) do not occur on or prior to December 31, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Shares and restricted stock units acquired pursuant to the exercise of 20,666 vested stock options under the Plan. The Reporting person received 13,164 freely tradable shares of Common Stock and 7,502 restricted stock units under the Plan, each restricted stock unit representing a right to receive one share of Common Stock. These restricted stock units remain in the Plan and are subject to forfeiture if the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) do not occur on or prior to December 31, 2022."}],"balance_after":33603,"derivative":{"underlying":"Common Stock","underlying_shares":7502},"source":{"system":"sec-edgar","filing":"0000950142-21-003504","document":"es210197022_4-daigneault.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1864648/000095014221003504/es210197022_4-daigneault.xml","form_type":"4"}},{"id":2529254,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":134013,"kind":"person","name":"Daigneault Alessandra","position":1,"cik":"0001864648","reported_name":"Daigneault Alessandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Restricted Stock Units","published_at":"2021-11-02T16:05:45.000Z","date":"2021-09-02","kind":"grant","acquired":true,"shares":10496,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Shares and restricted stock units acquired pursuant to the exercise of 28,916 vested stock options under the Plan. The Reporting person received 18,420 freely tradable shares of Common Stock and 10,496 restricted stock units under the Plan, each restricted stock unit representing a right to receive one share of Common Stock. These restricted stock units remain in the Plan and are subject to forfeiture if the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) do not occur on or prior to December 31, 2022."},{"field":"shares","element":"transactionShares","label":"F2","text":"Shares and restricted stock units acquired pursuant to the exercise of 28,916 vested stock options under the Plan. The Reporting person received 18,420 freely tradable shares of Common Stock and 10,496 restricted stock units under the Plan, each restricted stock unit representing a right to receive one share of Common Stock. These restricted stock units remain in the Plan and are subject to forfeiture if the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) do not occur on or prior to December 31, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Shares and restricted stock units acquired pursuant to the exercise of 28,916 vested stock options under the Plan. The Reporting person received 18,420 freely tradable shares of Common Stock and 10,496 restricted stock units under the Plan, each restricted stock unit representing a right to receive one share of Common Stock. These restricted stock units remain in the Plan and are subject to forfeiture if the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) do not occur on or prior to December 31, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Shares and restricted stock units acquired pursuant to the exercise of 28,916 vested stock options under the Plan. The Reporting person received 18,420 freely tradable shares of Common Stock and 10,496 restricted stock units under the Plan, each restricted stock unit representing a right to receive one share of Common Stock. These restricted stock units remain in the Plan and are subject to forfeiture if the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) do not occur on or prior to December 31, 2022."}],"balance_after":26101,"derivative":{"underlying":"Common Stock","underlying_shares":10496},"source":{"system":"sec-edgar","filing":"0000950142-21-003504","document":"es210197022_4-daigneault.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1864648/000095014221003504/es210197022_4-daigneault.xml","form_type":"4"}},{"id":2529253,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":134013,"kind":"person","name":"Daigneault Alessandra","position":1,"cik":"0001864648","reported_name":"Daigneault Alessandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Employee Stock Option (Right to buy)","published_at":"2021-11-02T16:05:45.000Z","date":"2021-09-02","kind":"exercise","acquired":false,"shares":20666,"price":3.07,"value":63444.62,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"From an option grant dated November 15, 2020; subject to certain conditions, the options will generally vest at a rate of 2066 every month commencing on 11/30/2020 through 10/30/1022 and the final 2,082 shares on 11/30/2022. As of September 1, 2021, 20,666 shares had vested and were available for exercise."}],"balance_after":28934,"derivative":{"exercise_price":3.07,"expiration_date":"2030-11-15","underlying":"Common Stock","underlying_shares":20666},"source":{"system":"sec-edgar","filing":"0000950142-21-003504","document":"es210197022_4-daigneault.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1864648/000095014221003504/es210197022_4-daigneault.xml","form_type":"4"}},{"id":2529252,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":134013,"kind":"person","name":"Daigneault Alessandra","position":1,"cik":"0001864648","reported_name":"Daigneault Alessandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Employee Stock Option (Right to buy)","published_at":"2021-11-02T16:05:45.000Z","date":"2021-09-02","kind":"exercise","acquired":false,"shares":28916,"price":3.07,"value":88772.12,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"From an option grant dated September 1, 2020; subject to certain conditions, the options will generally vest in 24 equal installments every month commencing on 09/30/2020 and fully vesting on 09/30/2022. As of September 1, 2021, 22,923 options had vested and were available for exercise."}],"balance_after":71924,"derivative":{"exercise_price":3.07,"expiration_date":"2030-09-01","underlying":"Common Stock","underlying_shares":28916},"source":{"system":"sec-edgar","filing":"0000950142-21-003504","document":"es210197022_4-daigneault.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1864648/000095014221003504/es210197022_4-daigneault.xml","form_type":"4"}},{"id":2529251,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":134013,"kind":"person","name":"Daigneault Alessandra","position":1,"cik":"0001864648","reported_name":"Daigneault Alessandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Restricted Stock Units","published_at":"2021-11-02T16:05:45.000Z","date":"2021-08-19","kind":"grant","acquired":true,"shares":15605,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Shares and restricted stock units acquired pursuant to the exercise of 43,000 vested stock options under the NRX Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan (the \"Plan\"). The Reporting person received 27,395 freely tradable shares of common stock, par value $0.001 per share, of NRX Pharmaceuticals, Inc. (the \"Common Stock \") and 15,605 restricted stock units, each restricted stock unit representing a right to receive one share of Common Stock. These restricted stock units remain in the Plan and are subject to forfeiture if the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) do not occur on or prior to December 31, 2022."},{"field":"shares","element":"transactionShares","label":"F1","text":"Shares and restricted stock units acquired pursuant to the exercise of 43,000 vested stock options under the NRX Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan (the \"Plan\"). The Reporting person received 27,395 freely tradable shares of common stock, par value $0.001 per share, of NRX Pharmaceuticals, Inc. (the \"Common Stock \") and 15,605 restricted stock units, each restricted stock unit representing a right to receive one share of Common Stock. These restricted stock units remain in the Plan and are subject to forfeiture if the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) do not occur on or prior to December 31, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares and restricted stock units acquired pursuant to the exercise of 43,000 vested stock options under the NRX Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan (the \"Plan\"). The Reporting person received 27,395 freely tradable shares of common stock, par value $0.001 per share, of NRX Pharmaceuticals, Inc. (the \"Common Stock \") and 15,605 restricted stock units, each restricted stock unit representing a right to receive one share of Common Stock. These restricted stock units remain in the Plan and are subject to forfeiture if the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) do not occur on or prior to December 31, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Shares and restricted stock units acquired pursuant to the exercise of 43,000 vested stock options under the NRX Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan (the \"Plan\"). The Reporting person received 27,395 freely tradable shares of common stock, par value $0.001 per share, of NRX Pharmaceuticals, Inc. (the \"Common Stock \") and 15,605 restricted stock units, each restricted stock unit representing a right to receive one share of Common Stock. These restricted stock units remain in the Plan and are subject to forfeiture if the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) do not occur on or prior to December 31, 2022."}],"balance_after":15605,"derivative":{"underlying":"Common Stock","underlying_shares":15605},"source":{"system":"sec-edgar","filing":"0000950142-21-003504","document":"es210197022_4-daigneault.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1864648/000095014221003504/es210197022_4-daigneault.xml","form_type":"4"}},{"id":2529250,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":134013,"kind":"person","name":"Daigneault Alessandra","position":1,"cik":"0001864648","reported_name":"Daigneault Alessandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Employee Stock Option (Right to buy)","published_at":"2021-11-02T16:05:45.000Z","date":"2021-08-19","kind":"exercise","acquired":false,"shares":43000,"price":3.07,"value":132010.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"From an option grant dated September 1, 2020; subject to certain conditions, the options will generally vest in 24 equal installments every month commencing on 09/30/2020 and fully vesting on 09/30/2022. As of September 1, 2021, 22,923 options had vested and were available for exercise."}],"balance_after":100840,"derivative":{"exercise_price":3.07,"expiration_date":"2030-09-01","underlying":"Common Stock","underlying_shares":43000},"source":{"system":"sec-edgar","filing":"0000950142-21-003504","document":"es210197022_4-daigneault.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1864648/000095014221003504/es210197022_4-daigneault.xml","form_type":"4"}},{"id":2529249,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":134013,"kind":"person","name":"Daigneault Alessandra","position":1,"cik":"0001864648","reported_name":"Daigneault Alessandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Common Stock","published_at":"2021-11-02T16:05:45.000Z","date":"2021-09-02","kind":"exercise","acquired":true,"shares":13164,"price":3.07,"value":40413.48,"ownership":{"direct":true},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F3","text":"Shares and restricted stock units acquired pursuant to the exercise of 20,666 vested stock options under the Plan. The Reporting person received 13,164 freely tradable shares of Common Stock and 7,502 restricted stock units under the Plan, each restricted stock unit representing a right to receive one share of Common Stock. These restricted stock units remain in the Plan and are subject to forfeiture if the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) do not occur on or prior to December 31, 2022."}],"balance_after":31584,"source":{"system":"sec-edgar","filing":"0000950142-21-003504","document":"es210197022_4-daigneault.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1864648/000095014221003504/es210197022_4-daigneault.xml","form_type":"4"}},{"id":2529248,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":134013,"kind":"person","name":"Daigneault Alessandra","position":1,"cik":"0001864648","reported_name":"Daigneault Alessandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Common Stock","published_at":"2021-11-02T16:05:45.000Z","date":"2021-09-02","kind":"exercise","acquired":true,"shares":18420,"price":3.07,"value":56549.4,"ownership":{"direct":true},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F2","text":"Shares and restricted stock units acquired pursuant to the exercise of 28,916 vested stock options under the Plan. The Reporting person received 18,420 freely tradable shares of Common Stock and 10,496 restricted stock units under the Plan, each restricted stock unit representing a right to receive one share of Common Stock. These restricted stock units remain in the Plan and are subject to forfeiture if the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) do not occur on or prior to December 31, 2022."}],"balance_after":18420,"source":{"system":"sec-edgar","filing":"0000950142-21-003504","document":"es210197022_4-daigneault.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1864648/000095014221003504/es210197022_4-daigneault.xml","form_type":"4"}},{"id":2529247,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":134013,"kind":"person","name":"Daigneault Alessandra","position":1,"cik":"0001864648","reported_name":"Daigneault Alessandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Common Stock","published_at":"2021-11-02T16:05:45.000Z","date":"2021-08-23","kind":"sale","acquired":false,"shares":33715,"price":13.11,"value":442003.65,"ownership":{"direct":true},"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950142-21-003504","document":"es210197022_4-daigneault.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1864648/000095014221003504/es210197022_4-daigneault.xml","form_type":"4"}},{"id":2529246,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":134013,"kind":"person","name":"Daigneault Alessandra","position":1,"cik":"0001864648","reported_name":"Daigneault Alessandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Common Stock","published_at":"2021-11-02T16:05:45.000Z","date":"2021-08-19","kind":"exercise","acquired":true,"shares":27395,"price":3.07,"value":84102.65,"ownership":{"direct":true},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Shares and restricted stock units acquired pursuant to the exercise of 43,000 vested stock options under the NRX Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan (the \"Plan\"). The Reporting person received 27,395 freely tradable shares of common stock, par value $0.001 per share, of NRX Pharmaceuticals, Inc. (the \"Common Stock \") and 15,605 restricted stock units, each restricted stock unit representing a right to receive one share of Common Stock. These restricted stock units remain in the Plan and are subject to forfeiture if the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) do not occur on or prior to December 31, 2022."}],"balance_after":33715,"source":{"system":"sec-edgar","filing":"0000950142-21-003504","document":"es210197022_4-daigneault.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864648/000095014221003504/es210197022_4-daigneault.xml","form_type":"4"}},{"id":2674221,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":134013,"kind":"person","name":"Daigneault Alessandra","position":1,"cik":"0001864648","reported_name":"Daigneault Alessandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Employee Stock Option (Right to buy)","published_at":"2021-06-10T18:45:42.000Z","date":"2021-05-24","kind":"grant","acquired":true,"shares":148800,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each option and warrant of NeuroRx that was outstanding and unexercised immediately prior to the Effective Time was assumed by NRX Pharmaceuticals (each, a \"Substitute Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. In the event that any Substitute Security is exercised prior to the earlier of the date on which both the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) have been achieved and December 31, 2022, a number of shares of the Issuer's common stock will be subject to forfeiture pursuant to the Option Post-Earnout Adjustment (as defined in the Merger Agreement)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each option and warrant of NeuroRx that was outstanding and unexercised immediately prior to the Effective Time was assumed by NRX Pharmaceuticals (each, a \"Substitute Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. In the event that any Substitute Security is exercised prior to the earlier of the date on which both the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) have been achieved and December 31, 2022, a number of shares of the Issuer's common stock will be subject to forfeiture pursuant to the Option Post-Earnout Adjustment (as defined in the Merger Agreement)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Subject to certain conditions, the options will generally vest in twenty four equal installments every month commencing on 04/30/21 and fully vesting on 04/30/23."}],"balance_after":148800,"derivative":{"exercise_price":72.3,"expiration_date":"2031-04-21","underlying":"Common Stock","underlying_shares":148800},"source":{"system":"sec-edgar","filing":"0000950142-21-001937","document":"es210157181_4-daigneault.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1864648/000095014221001937/es210157181_4-daigneault.xml","form_type":"4"}},{"id":2674220,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":134013,"kind":"person","name":"Daigneault Alessandra","position":1,"cik":"0001864648","reported_name":"Daigneault Alessandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Employee Stock Option (Right to buy)","published_at":"2021-06-10T18:45:42.000Z","date":"2021-05-24","kind":"grant","acquired":true,"shares":49600,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each option and warrant of NeuroRx that was outstanding and unexercised immediately prior to the Effective Time was assumed by NRX Pharmaceuticals (each, a \"Substitute Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. In the event that any Substitute Security is exercised prior to the earlier of the date on which both the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) have been achieved and December 31, 2022, a number of shares of the Issuer's common stock will be subject to forfeiture pursuant to the Option Post-Earnout Adjustment (as defined in the Merger Agreement)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each option and warrant of NeuroRx that was outstanding and unexercised immediately prior to the Effective Time was assumed by NRX Pharmaceuticals (each, a \"Substitute Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. In the event that any Substitute Security is exercised prior to the earlier of the date on which both the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) have been achieved and December 31, 2022, a number of shares of the Issuer's common stock will be subject to forfeiture pursuant to the Option Post-Earnout Adjustment (as defined in the Merger Agreement)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Subject to certain conditions, the options will generally vest at a rate of 416 every month commencing on 11/30/20 through 10/30/22 and the final 432 shares on 11/30/22."}],"balance_after":49600,"derivative":{"exercise_price":3.08,"expiration_date":"2030-11-15","underlying":"Common Stock","underlying_shares":49600},"source":{"system":"sec-edgar","filing":"0000950142-21-001937","document":"es210157181_4-daigneault.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1864648/000095014221001937/es210157181_4-daigneault.xml","form_type":"4"}},{"id":2674219,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":134013,"kind":"person","name":"Daigneault Alessandra","position":1,"cik":"0001864648","reported_name":"Daigneault Alessandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Employee Stock Option (Right to buy)","published_at":"2021-06-10T18:45:42.000Z","date":"2021-05-24","kind":"grant","acquired":true,"shares":143840,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each option and warrant of NeuroRx that was outstanding and unexercised immediately prior to the Effective Time was assumed by NRX Pharmaceuticals (each, a \"Substitute Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. In the event that any Substitute Security is exercised prior to the earlier of the date on which both the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) have been achieved and December 31, 2022, a number of shares of the Issuer's common stock will be subject to forfeiture pursuant to the Option Post-Earnout Adjustment (as defined in the Merger Agreement)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each option and warrant of NeuroRx that was outstanding and unexercised immediately prior to the Effective Time was assumed by NRX Pharmaceuticals (each, a \"Substitute Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. In the event that any Substitute Security is exercised prior to the earlier of the date on which both the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) have been achieved and December 31, 2022, a number of shares of the Issuer's common stock will be subject to forfeiture pursuant to the Option Post-Earnout Adjustment (as defined in the Merger Agreement)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Subject to certain conditions, the options will generally vest in twenty four equal installments every month commencing on 09/30/20 and fully vesting on 09/30/22."}],"balance_after":143840,"derivative":{"exercise_price":3.08,"expiration_date":"2030-09-01","underlying":"Common Stock","underlying_shares":143840},"source":{"system":"sec-edgar","filing":"0000950142-21-001937","document":"es210157181_4-daigneault.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1864648/000095014221001937/es210157181_4-daigneault.xml","form_type":"4"}},{"id":2674218,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":134013,"kind":"person","name":"Daigneault Alessandra","position":1,"cik":"0001864648","reported_name":"Daigneault Alessandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Common Stock","published_at":"2021-06-10T18:45:42.000Z","date":"2021-05-24","kind":"grant","acquired":true,"shares":6320,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 24, 2021, pursuant to that certain Agreement and Plan of Merger dated December 13, 2020 (the \"Merger Agreement\") among NRX Pharmaceuticals, Inc. (f/k/a Big Rock Partners Acquisition Corp) (the \"Issuer\"), Big Rock Merger Corp., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer (\"Merger Sub\"), and NeuroRx, Inc. (\"NeuroRx\"), Merger Sub merged with and into NeuroRx (the \"Merger\"), with NeuroRx surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each share of NeuroRx common stock was automatically converted into the right to receive a pro rata portion of 50,000,000 shares of the Issuer's common stock and the contingent right to receive a pro rata portion of 25,000,000 shares of the Issuer's common stock (the \"Earnout Shares\") and Earnout Cash (as defined in the Merger Agreement)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Merger Agreement provides that the former shareholders of NeuroRx will receive a pro rata portion of the Earnout Shares if, prior to December 31, 2022, the NeuroRx COVID-19 Drug (i.e., ZYESAMI) receives emergency use authorization by the Food and Drug Administration (the ?FDA?) and NeuroRx submits and the FDA files for review a new drug application for the NeuroRx COVID-19 Drug (i.e., ZYESAMI) (the \"Earnout Shares Milestone\"). The Reporting Person?s right to receive additional shares pursuant to this earn-out right became fixed and irrevocable on May 24, 2021, the effective date of the Merger."}],"balance_after":6320,"source":{"system":"sec-edgar","filing":"0000950142-21-001937","document":"es210157181_4-daigneault.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864648/000095014221001937/es210157181_4-daigneault.xml","form_type":"4"}}]}